Scientific Advisory Board

Opexa utilizes a team of industry and academic experts to help guide the company in strategic decision-making. Each member of Opexas Scientific Advisory Board is internationally recognized as a leading expert in their field.

Dawn McGuire, M.D. (Chair)

Dr. McGuire is the Chair of Opexas Scientific Advisory Board and the Companys acting chief medical officer. She is a board certified neurologist with more than a decade of executive leadership in drug development. Previously, Dr. McGuire was vice president of clinical research at Elan Pharmaceuticals where she served as development leader for Tysabri, a drug now marketed for the treatment of patients with relapsing forms of multiple sclerosis (MS). Dr. McGuire also holds several academic and service positions, including American Academy of Neurology committee memberships, peer review committee membership in the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH), and serves on the Advisory Council of the Gill Heart Institute.

Hans-Peter Hartung, M.D.

Dr. Hartung holds the Chair of Neurology at Heinrich-Heine University, Düsseldorf and is chairman of the Department of Neurology. Professor Hartung is a member of a large number of international and national societies, serving on executive boards (President ECTRIMS; European Neurological Society, International Society for Neuroimmunology, International Federation of Multiple Sclerosis Societies; World Health Organization Advisory Board on Multiple Sclerosis), as well as on the editorial board of a number of international journals. He has authored or co-authored more than 400 articles in peer reviewed journals, written more than 80 book chapters and edited 7 books on neurology, neuroimmunology, peripheral nerve disease and multiple sclerosis.

Paul OConnor, M.D.

Dr. OConnor is a neurologist and MS Clinic Director at St. Michaels Hospital, University of Toronto where he serves as Professor of Medicine Neurology. He holds the appointment of National Scientific and Clinical Advisor for the Multiple Sclerosis Society of Canada. He is past president of the Canadian Network of MS Clinics. Dr. OConnor is a leading clinical investigator and respected key opinion leader in the field of MS having written over 150 clinical and scientific articles. He is a world authority on the design and implementation of clinical trials in MS and has served as lead-investigator or on the steering committee of trials for several new agents including monoclonal antibodies, natalizumab and rituxumab, as well as fingolimond, taxol and various interferons.

Clyde Markowitz, M.D.

Dr. Markowitz is the Director of the Multiple Sclerosis Center at the University of Pennsylvania and Professor of Neurology at the University of Pennsylvania School of Medicine in Philadelphia. His expertise is in the field of multiple sclerosis and is involved with many clinical trials developing new compounds for the treatment of MS. He currently serves as the Chairman of the Clinical Advisory Committee for the Delaware Valley chapter of the National Multiple Sclerosis Society. Dr. Markowitz is the author of a number of publications, and he serves as an ad hoc reviewer to several important scholarly publications. He is a member of the American Academy of Neurology.

Doug Arnold, M.D.

Dr. Arnold is the James McGill Professor of Neurology and Neurosurgery at the Montreal Neurological Institute of McGill University. He directs a research laboratory using world class advanced MRI acquisition and analysis techniques to improve the understanding of how brain injury and repair in MS evolve and how they are subsequently influenced by therapeutic interventions.

Edward Fox, M.D., Ph.D.

Dr. Fox is the director of Multiple Sclerosis Clinic of Central Texas and is also trained as an immunologist. He is on the advisory committee for the Lone Star Chapter of the National Multiple Sclerosis Society, and is a member of the Consortium of Multiple Sclerosis Centers. Dr. Fox has been appointed Clinical Assistant Professor of Neurology for the University of Texas Medical Branch and is leading student and resident training in neuroimmunology and the role of clinical research in medical private practice.

Mark S. Freedman, M.D.

Dr. Freedman is currently professor of medicine in the field of neurology at the University of Ottawa, as well as director of the Multiple Sclerosis Research Unit at the Ottawa Hospital, General Campus. A graduate of the University of Toronto, Dr. Freedman holds his Masters Degree in Molecular Neurochemistry and continued his postgraduate work specializing in neurology and neuroimmunology after medical school. Dr. Freedman has published over 250 pieces, including articles, books, book chapters and abstracts. He has over 25 years of experience in the management of patients with multiple sclerosis and has been the principal investigator on numerous clinical trials with new therapeutic agents for MS. Dr. Freedman also serves on the editorial boards for several journals, including the Multiple Sclerosis Journal, and is active on several national and international committees including the Multiple Sclerosis Society of Canada, National MS Society (USA), the Americas Committee for Treatment and Research in MS (ACTRIMS) and the Consortium of MS Centres (CMSC).